Corticorelin Market Opportunity in Peritumoral Brain Edema (PTBE) expected to exceed USD 1 billion; Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog LIESTAL, Switzerland--(BUSINESS WIRE)- ...
Curatis’ lead product candidate, C-PTBE-01 (corticorelin), is being developed to treat peritumoral brain edema (PTBE). PTBE occurs in association with many primary and metastatic (secondary) brain ...
The issuer is solely responsible for the content of this announcement. Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated the ability to positively impact the blood-brain ...
Japan is one of the world's most important pharmaceutical markets after the US and Europe. Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well ...
Curatis Holding (SIX:CURN) has explored in detail which regulatory pathway should be pursued in view of a possible approval of C-PBTE-01 in the USA. The detailed clarifications in collaboration with a ...
* Curatis Holding AG acquired Curatis AG effective on 26 April 2024, and the acquisition is based on the values of the audited opening balance sheet as per 30 April 2024. Therefore, the financial ...
An epidemiological market study commissioned by Curatis Holding AG (SIX:CURN, “Curatis”) shows that the target patient group is substantially larger than previous estimates. In the US alone, over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results